With the FreeStyle Libre family of products, you know what impacts your glucose.
The MyFreeStyle program helps guide you through your first CGM experience.
CGM = continuous glucose monitoring
Track your activities in the reader to unlock insights about what impacts your glucose levels1,2
Get 14 days of guided support that can help lower your A1c levelsII3,4
For illustrative purposes only. Not actual patient data.
Discover more affordable CGM systems¶#5
Most commercially insured patients pay between $0 to $60 per month for FreeStyle Libre 2 or FreeStyle Libre 14 day sensors,‡**††5 and no more than $65 for a FreeStyle Libre 2 or FreeStyle Libre 14 day reader (at participating pharmacies).‡§§‡‡5
The FreeStyle Libre 2 app* and the FreeStyle LibreLink appIIII let you scan your sensors using a compatible smartphone instead of a reader.দ##*** Now you can download the FreeStyle Libre 2 app* from the Apple App Store or Google Play for free.
Make more informed decisionsII6:
CGM automatically tracks your glucose levels day and night using a small sensor worn on the back of the upper arm and a monitor that lets you view your glucose‡‡‡ levels at any time§§§
Unlike a blood glucose monitor, which only gives you a current glucose reading, CGM shows additional insights into where your glucose level was, currently is, and where it’s headed
Medicare coverage is available for the FreeStyle Libre 2 system if a compatible smartphone is used in conjunction with the FreeStyle Libre 2 reader to review glucose data. Medicare and other third party payor criteria apply.
As a courtesy, Abbott provides the most up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.
* The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.
† or ♢ Eligible patients will receive one (1) FreeStyle Libre 2 sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with Type 1 and Type 2 diabetes; it is not available for patients with gestational diabetes. Only patients ages 18 and older are eligible to sign up and receive an offer for the FreeStyle Libre 2 sensor and patients ages 4-17 are eligible to receive an offer for the FreeStyle Libre 2 sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs or residents of Massachusetts, Puerto Rico and other US territories. The free FreeStyle Libre 2 sensor is provided as a sample and is limited to one NDC per eligible person. The FreeStyle Libre 2 sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.
‡ As a courtesy, Abbott provides the most up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.
§ Medicare coverage is available for the FreeStyle Libre 2 system if a compatible smartphone is used in conjunction with the FreeStyle Libre 2 reader to review glucose data. Medicare and other third party payor criteria apply.
II Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.
¶ Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
# Based on a comparison of list prices of the FreeStyle Libre 14 day system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
** Based on prescription claims for commercially insured patients using the FreeStyle Libre 14 day system. Does not include Medicare, Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre 14 day system requires a prescription.
†† Based on prescription claims for commercially insured patients using the FreeStyle Libre 2 system. Does not include Medicare, Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre 2 system requires a prescription.
‡‡ Benefits for FreeStyle Libre 14 day sensors apply to two 14 day sensors per month. Benefits for FreeStyle Libre 14 day reader apply to one 14 day reader. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. Offer available to commercially insured patients only. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs, or residents of US territories and possessions, except Puerto Rico. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary. The FreeStyle Libre 14 day system requires a prescription.
§§ Benefits for FreeStyle Libre 2 sensors apply to two FreeStyle Libre 2 sensors per month. Benefits for FreeStyle Libre 2 reader apply to one FreeStyle Libre 2 reader. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. Offer available to commercially insured patients only. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary. The FreeStyle Libre 2 system requires a prescription.
IIII The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle LibreLink app requires registration with LibreView.
¶¶ Medicare coverage is available for FreeStyle Libre 14 day systems for cell phone use if FreeStyle LibreLink is used in conjunction with the FreeStyle Libre 14 day readers. See Local Coverage Determination: Glucose Monitors (L33822), July 2021 and Local Coverage Article: Glucose Monitors (A52464), July 2021.
## The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
*** The FreeStyle LibreLink app and the FreeStyle Libre 14 day reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
††† On May 8, 2020, CMS published a second interim final rule with comment, CMS-5531-IFC, that expanded the non-enforcement of clinical indications of coverage to therapeutic continuous glucose monitors (CGMs). (www.govinfo.gov/content/pkg/FR-2020-05-08/pdf/2020-09608.pdf) The Durable Medical Equipment Medicare Administrative Contractors (DME MAC) subsequently issued guidance on the IFC policies, including discussing that clinical indications for coverage in the therapeutic CGM LCD (Glucose Monitors, L33822) will not be enforced. See “CMS Issues Interim Final Rules with Comment (CMS-1744-IFC & CMS-5531-IFC) – COVID-19 Public Health Emergency – Revised May 21, 2020.” (www.cgsmedicare.com/jc/pubs/news/2020/05/cope1733) As a courtesy to its customers, Abbott provides the most accurate and up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third-party coverage of payment for our products or reimburse customers for claims that are denied by third-party payors.
‡‡‡ Based on the sensor being replaced once every 14 days, and scanned at least once every 8 hours.
§§§ Glucose readings are not available during 1-hour warm-up, when sensor is too hot or too cold, or when you see an error, "LO" or "HI" message, or no current glucose reading.
References: 1. FreeStyle Libre 2 User’s Manual. 2. FreeStyle Libre 14 day User’s Manual. 3. Kroeger, Jens, Peter Fasching, and Helene Hanaire. "Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes." Diabetes Therapy 11, no. 1 (January 2020): 279-291. https://doi.org/10.1007/s13300-019-00741-9. 4. Evans, Mark, et al. "The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-world Observational Studies." Diabetes Therapy 11, no. 1 (January 2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 5. Data on File. Abbott Diabetes Care. 6. Unger, Jeff, Pamela Kushner, and John E. Anderson. "Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care." Postgraduate Medicine 132, no 4. (March 2020): 305-313. https://doi.org/10.1080/00325481.2020.1744393.
Abbott supports patient access to the FreeStyle Libre family of products through a variety of programs, including trial offers, that may reduce the out-of-pocket amounts that patients must pay. The actual amount that a patient may pay may vary or change based on factors such as the duration of the program, product insurance coverage status, state of residence, or other eligibility limitations. Abbott may modify, rescind, or revoke these programs at any time without notice.
ADC-12211 Ver 20.0 12/21
Medicare coverage is available for the FreeStyle Libre 2 system if a compatible smartphone is used in conjunction with the FreeStyle Libre 2 reader to review glucose data. Medicare and other third party payor criteria apply.
As a courtesy, Abbott provides the most up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.
* The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.
† or ♢ Eligible patients will receive one (1) FreeStyle Libre 2 sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with Type 1 and Type 2 diabetes; it is not available for patients with gestational diabetes. Only patients ages 18 and older are eligible to sign up and receive an offer for the FreeStyle Libre 2 sensor and patients ages 4-17 are eligible to receive an offer for the FreeStyle Libre 2 sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs or residents of Massachusetts, Puerto Rico and other US territories. The free FreeStyle Libre 2 sensor is provided as a sample and is limited to one NDC per eligible person. The FreeStyle Libre 2 sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.
‡ As a courtesy, Abbott provides the most up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.
§ Medicare coverage is available for the FreeStyle Libre 2 system if a compatible smartphone is used in conjunction with the FreeStyle Libre 2 reader to review glucose data. Medicare and other third party payor criteria apply.
II Data from this study was collected with the outside US version of FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional, real-time glucose alarms. Therefore, the study data is applicable to both products.
¶ Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
# Based on a comparison of list prices of the FreeStyle Libre 14 day system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
** Based on prescription claims for commercially insured patients using the FreeStyle Libre 14 day system. Does not include Medicare, Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre 14 day system requires a prescription.
†† Based on prescription claims for commercially insured patients using the FreeStyle Libre 2 system. Does not include Medicare, Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre 2 system requires a prescription.
‡‡ Benefits for FreeStyle Libre 14 day sensors apply to two 14 day sensors per month. Benefits for FreeStyle Libre 14 day reader apply to one 14 day reader. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. Offer available to commercially insured patients only. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs, or residents of US territories and possessions, except Puerto Rico. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary. The FreeStyle Libre 14 day system requires a prescription.
§§ Benefits for FreeStyle Libre 2 sensors apply to two FreeStyle Libre 2 sensors per month. Benefits for FreeStyle Libre 2 reader apply to one FreeStyle Libre 2 reader. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. Offer available to commercially insured patients only. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary. The FreeStyle Libre 2 system requires a prescription.
IIII The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle LibreLink app requires registration with LibreView.
¶¶ Medicare coverage is available for FreeStyle Libre 14 day systems for cell phone use if FreeStyle LibreLink is used in conjunction with the FreeStyle Libre 14 day readers. See Local Coverage Determination: Glucose Monitors (L33822), July 2021 and Local Coverage Article: Glucose Monitors (A52464), July 2021.
## The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
*** The FreeStyle LibreLink app and the FreeStyle Libre 14 day reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
††† On May 8, 2020, CMS published a second interim final rule with comment, CMS-5531-IFC, that expanded the non-enforcement of clinical indications of coverage to therapeutic continuous glucose monitors (CGMs). (www.govinfo.gov/content/pkg/FR-2020-05-08/pdf/2020-09608.pdf) The Durable Medical Equipment Medicare Administrative Contractors (DME MAC) subsequently issued guidance on the IFC policies, including discussing that clinical indications for coverage in the therapeutic CGM LCD (Glucose Monitors, L33822) will not be enforced. See “CMS Issues Interim Final Rules with Comment (CMS-1744-IFC & CMS-5531-IFC) – COVID-19 Public Health Emergency – Revised May 21, 2020.” (www.cgsmedicare.com/jc/pubs/news/2020/05/cope1733) As a courtesy to its customers, Abbott provides the most accurate and up-to-date information available, but it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third-party coverage of payment for our products or reimburse customers for claims that are denied by third-party payors.
‡‡‡ Based on the sensor being replaced once every 14 days, and scanned at least once every 8 hours.
§§§ Glucose readings are not available during 1-hour warm-up, when sensor is too hot or too cold, or when you see an error, "LO" or "HI" message, or no current glucose reading.
References: 1. FreeStyle Libre 2 User’s Manual. 2. FreeStyle Libre 14 day User’s Manual. 3. Kroeger, Jens, Peter Fasching, and Helene Hanaire. "Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes." Diabetes Therapy 11, no. 1 (January 2020): 279-291. https://doi.org/10.1007/s13300-019-00741-9. 4. Evans, Mark, et al. "The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-world Observational Studies." Diabetes Therapy 11, no. 1 (January 2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 5. Data on File. Abbott Diabetes Care. 6. Unger, Jeff, Pamela Kushner, and John E. Anderson. "Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care." Postgraduate Medicine 132, no 4. (March 2020): 305-313. https://doi.org/10.1080/00325481.2020.1744393.
Abbott supports patient access to the FreeStyle Libre family of products through a variety of programs, including trial offers, that may reduce the out-of-pocket amounts that patients must pay. The actual amount that a patient may pay may vary or change based on factors such as the duration of the program, product insurance coverage status, state of residence, or other eligibility limitations. Abbott may modify, rescind, or revoke these programs at any time without notice.
ADC-12211 Ver 20.0 12/21
Important Safety Information
FreeStyle Libre 14 day system: Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.
FreeStyle Libre 2 system: Failure to use FreeStyle Libre 2 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.
The product images are for illustrative purposes only.
The circular shape of the sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-29111 Ver 9.0 01/22
For more information about COVID-19, please click here
